UM Scientists Restore Guinea Pig's Hearing
Editor: Here's some good news for people who are interested in hair
cell regeneration as a cure for hearing loss. Scientists at the University
of Michigan have restored a guinea pig's hearing! Note, however, that we
are still a long ways from turning this procedure into an effective
commercial treatment. Please see the caveat at the end of this article.
~~~~~~~~~~~~~~~~~
February 2005
After 11 years of intensive research, scientists at the University of
Michigan Medical School have succeeded in using gene therapy to grow new
auditory hair cells and restore hearing in deafened adult guinea pigs - a
major step forward in the search for new ways to treat hearing loss in
humans.
Results from the study - the first to demonstrate restoration of
auditory hair cells at the structural and functional levels in mature
living mammals - will be published Feb.13 on Nature Medicine's advance
online publication Web site.
Hair cells are the sensory cells of the auditory and balance organs in
the inner ear. Auditory hair cells reside in the organ of Corti, which is
part of the cochlea - a spiral-shaped bony organ in the inner ear. They
get their name from the numerous microscopic hair-like projections that
grow from each cell.
When sound waves reach the inner ear, they cause these projections to
move. This triggers electrical signals, which are picked up by auditory
nerve fibers and carried to the brain. If hair cells are damaged or
missing, the connection between sound waves and the brain's auditory
processing center is broken, making it impossible to hear.
Aging, infections, certain medications, autoimmune diseases, and
exposure to loud sounds can destroy the delicate hair cells, leading to
irreversible sensorineural hearing loss - a condition affecting millions
of people worldwide.
For years, scientists have been searching for a way to regenerate
functioning hair cells.
Yehoash Raphael, Ph.D., an associate professor of otolaryngology at
U-M's Kresge Hearing Research Institute, who directed the U-M study,
credits advances made by other scientists worldwide for his team's
success. "Progress in gene delivery methods and in understanding of the
molecular mechanism that controls hair cell development facilitated the
experimental approach used by our group," Raphael says.
"We inserted a gene called Atoh1, a key regulator of auditory hair cell
development, into non-sensory epithelial cells that remain in the deafened
inner ears of adult guinea pigs, whose original hair cells were destroyed
by exposure to ototoxic drugs," Raphael explains. "Eight weeks after
treatment, we found new auditory hair cells in the Atoh1 -treated ears of
the research animals. Auditory tests indicated that the generation of new
hair cells coincided with restoration of hearing thresholds."
Raphael describes Atoh1 (formerly known as Math1) as a "pro-hair cell
gene," which normally is active only during embryonic development.
Originally discovered in fruit flies, the gene is present in all animals,
including humans. During the embryonic stage of animal development, Atoh1
is turned on, or expressed, in inner ear cells destined to become hair
cells, while its expression is inhibited in supporting (non-sensory)
cells.
"Our goal was to find a way to activate Atoh1 in mature non-sensory
cells in the inner ear, causing them to develop into new hair cells,"
Raphael says.
The first author of the paper, Masahiko Izumikawa, M.D., is a research
fellow from Kansai Medical University in Osaka, Japan, who is now training
with Raphael at the U-M Medical School. Izumikawa used an adenoviral
vector to deliver the Atoh1 gene to inner ear cells. He injected the Atoh1
vector into the left ears of 10 guinea pigs that had received large doses
of ototoxic drugs four days earlier to destroy their hair cells. The same
procedure, but without transfer of the Atoh1 gene, was performed on
matched control animals. The right ears of the deafened animals did not
receive the Atoh1 treatment and served as an additional control.
Microscopic images of inner ears from deafened animals taken three days
after ototoxic drug treatment confirmed that the drugs had destroyed all
the hair cells. However, images of inner ears treated with Atoh1, taken
eight weeks after inoculation, showed large numbers of hair cells in the
cochlea. Images of control ears treated with the vector alone, or with the
vector in combination with green fluorescent protein, showed no hair
cells. Contralateral (right, untreated) ears were also devoid of hair
cells.
"Because we eliminated all the original hair cells in the organ of
Corti, we know that any new hair cells must have developed from
non-sensory cells, which were induced by Atoh1 gene expression to change
into auditory hair cells," Izumikawa says.
To find out whether the new hair cells were actually functional, U-M
scientists used tests of auditory brainstem response or ABR, similar to
those given to humans to test their ability to hear sound. These tests
measure auditory thresholds - the lowest level of sound intensity that
generates a response in the brainstem.
"Four weeks after treatment, the threshold levels indicated profound
deafness. But at eight weeks, average thresholds in Atoh1 -treated ears
were lower (better) at all frequencies than in the control ears. This is
the most exciting finding of our study," says Raphael, who adds that he
repeated the tests four times to be sure of his results.
Restoring auditory threshold levels is an important advance, but
Raphael cautions that it shouldn't be considered the same as restoring
normal hearing. "At this early stage the structural and functional repairs
are incomplete and the hearing of these animals is likely to be
distorted," he says. "For this and other reasons, it will be several years
before Atoh1 gene therapy is ready for human testing."
In future research, Raphael plans to test Atoh1 treatment in aged
animals and animals deafened by noise exposure, rather than drugs. He also
wants to determine if the treatment is effective months or years after the
original hair cells have degenerated.
Previous research by Raphael and his U-M team, published in the June 1,
2003 issue of the Journal of Neuroscience, demonstrated it was possible to
grow new hair cells in non-deafened guinea pigs by inserting Atoh1 into
non-sensory epithelial cells lining the inner ear.
The research was supported by the National Institute on Deafness and
Other Communication Disorders of the National Institutes of Health, a gift
from Berte and Alan Hirschfield, Center for Hearing Disorders, and GenVec,
Inc., a biopharmaceutical company in Gaithersburg , Md. GenVec provided
its proprietary adenovector with the Atoh1 gene insert . Douglas E. Brough,
a co-author of the paper, is a GenVec employee. Raphael has no financial
interest in the company.
Additional collaborators and co-authors include Ryosei Minoda, M.D.,
and Kohei Kawamoto, M.D., former U-M research fellows; Karen A. Abrashkin,
former U-M undergraduate student; Donald L. Swiderski, Ph.D., research
associate; and David F. Dolan, Ph.D., U-M research associate professor.
Nature Medicine's Advance Online Publication page:
www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/vaop/ncurrent/index.html
To learn about previous research from the Raphael lab:
www.med.umich.edu/opm/newspage/2003/haircells.htm
Special notes on this release
Thank you for your inquiry about the recent announcement that U-M
scientists have used gene therapy to grow new auditory hair cells and
restore hearing in deafened guinea pigs. The scientists in Dr. Raphael's
laboratory sincerely appreciate the excitement this research has
generated.
We know there are millions of people with profound hearing loss waiting
for new, more effective treatments. Because of the volume of calls and
e-mails we've received, we are unable to answer everyone individually.
While this is an important scientific discovery, please remember that
many years of additional research will be needed before this technology
can be tested in human beings. Before new therapies can be offered to
patients, we must be sure they are safe and effective in animals. U-M
scientists are working to complete this initial stage of the research as
quickly as possible.
At this point, there are no immediate plans for clinical trials -
either at the U-M Health System or, to the best of our knowledge, at other
institutions. If you'd like more information about current research in Dr.
Raphael's lab, go to www.khri.med.umich.edu/research/raphael_lab/index.shtml.